The North America PARP inhibitor biomarkers testing product market is experiencing significant expansion due to growing awareness of personalized medicine, increasing cancer incidence, and rapid advancements in molecular diagnostics. The region benefits from a well-established healthcare ecosystem, strong government support for cancer research, and widespread access to genomic testing...